NeoGenomics (NEO) vs UL Solutions (ULS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
NeoGenomics (NEO) has outperformed UL Solutions (ULS) over the past year, gaining 29.1% versus a loss of 15.2%. UL Solutions is the larger company by market cap ($14.67 billion vs $1.92 billion), about 7.6 times the size, while NeoGenomics is growing revenue faster (+10.1% vs +6.4%). On valuation, UL Solutions trades at a lower forward P/E (27.5x vs 47.1x for NeoGenomics).
UL Solutions pays a dividend yielding 0.78%, while NeoGenomics does not currently pay one. UL Solutions converts more of its revenue into profit, with a net margin of 10.6% versus -14.9%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | NEO | ULS |
|---|---|---|
| Share price | $14.82 | $72.64 |
| Market cap | $1.92B | $14.67B |
| 1-day change | -1.79% | -2.99% |
| YTD return | +26.02% | -7.89% |
| 1-year return | +29.09% | -15.24% |
| 5-year return | -59.56% | — |
| P/E ratio (TTM) | — | 28.83 |
| Forward P/E | 47.11 | 27.49 |
| EPS (TTM) | $-0.24 | $2.52 |
| Dividend yield | 0.00% | 0.78% |
| Annual dividend | $0.00 | $0.565 |
| Revenue (latest FY) | $727.33M | $3.05B |
| Revenue growth (YoY) | +10.11% | +6.38% |
| Net income (latest FY) | $-108.03M | $325.00M |
| Gross margin | 43.21% | 49.46% |
| Operating margin | -15.93% | 17.10% |
| Net margin | -14.85% | 10.65% |
| 52-week high | $20.15 | $107.54 |
| 52-week low | $7.07 | $63.17 |
| Distance from 52-week high | -26.45% | -32.45% |
| Analyst consensus | none | buy |
| Avg. price target upside | +57.89% | +32.78% |
| Average volume | 1.96M | 873.95K |
| Shares outstanding | 129.39M | 78.15M |
| Employees | 2,500 | 14,587 |
| Sector | Health Care | Health Care |
| Industry | Precision Instruments | Precision Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- UL Solutions is about 7.6 times larger than NeoGenomics by market value ($14.67B vs $1.92B).
- NEO has outperformed ULS by 44.3 percentage points over the past year.
- UL Solutions is more profitable, keeping 10.6 cents of every revenue dollar as net income versus -14.9 cents for NeoGenomics.
About NeoGenomics
NEO stock →NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom.
Health Care · Precision Instruments · 2,500 employees
About UL Solutions
ULS stock →UL Solutions Inc., together with its subsidiaries, provides testing, inspection and certification services and related software and advisory services worldwide. It operates through three segments: Industrial, Consumer, and Software and Advisory.
Health Care · Precision Instruments · 14,587 employees
NEO vs ULS FAQ
Which is bigger, NeoGenomics or UL Solutions?
UL Solutions (ULS) is larger, with a market capitalization of $14.67B compared with $1.92B for NeoGenomics (NEO).
Which stock has performed better over the past year, NEO or ULS?
NEO returned +29.09% over the past 12 months, compared with -15.24% for ULS (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, NeoGenomics or UL Solutions?
UL Solutions pays a dividend yielding 0.78%, while NeoGenomics does not currently pay a regular dividend.
Are NeoGenomics and UL Solutions in the same industry?
Yes. Both are classified in the Precision Instruments industry within the Health Care sector.